A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects
Study Details
Study Description
Brief Summary
The primary objectives of this 2-part drug interaction study are as follows:
-
To evaluate the effect of gemfibrozil on the pharmacokinetics (i.e., amount in the blood) of selexipag and its metabolite ACT-333679 (Part I).
-
To evaluate the effect of rifampicin on the pharmacokinetics of selexipag and its metabolite ACT-333679 (Part II).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
Because non-clinical studies have shown that selexipag and its active metabolite, ACT-333679, are substrates for cytochrome P450 2C8 (CYP2C8), the present clinical study aims at investigating the effect of a strong inhibitor (gemfibrozil) and a moderate inducer (rifampicin) of CYP2C8 on the pharmacokinetic of selexipag and ACT-333679 as recommended by the FDA's Guidance for Industry Drug Interaction Studies (FDA, 2012).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Part 1, sequence AB Subjects participate in two study periods: During the first period (Treatment A), they receive oral selexipag on Day 1. During the second period (Treatment B), they receive multiple oral dose of gemfibrozil from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 4 concomitantly with gemfibrozil. There is a washout period of 14 to 21 days between the two periods. |
Drug: Selexipag
Two selexipag film-coated tablets of 200 µg as single oral dose (total dose = 400 µg)
Other Names:
Drug: Gemfibrozil
Gemfibrozil film-coated tablet of 600 mg administered orally b.i.d. from Day 1 to Day 9
|
| Experimental: Part 1, sequence BA Subjects participate in two study periods: During the first period (Treatment B), they receive multiple oral dose of gemfibrozil from Day 1 to Day 9. They also receive a single oral dose of selexipag on Day 4 concomitantly with gemfibrozil. During the second period (Treatment A) they receive oral selexipag on Day 1. There is a washout period of 14 to 21 days between the two periods. |
Drug: Selexipag
Two selexipag film-coated tablets of 200 µg as single oral dose (total dose = 400 µg)
Other Names:
Drug: Gemfibrozil
Gemfibrozil film-coated tablet of 600 mg administered orally b.i.d. from Day 1 to Day 9
|
| Experimental: Part 2, sequence AB Subjects participate in two study periods: During the first period (Treatment A), they receive oral selexipag on Day 1. During the second period (Treatment B), they receive rifampicin once daily from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 7 together with the dose of rifampicin.There is a washout period of 14 to 21 days between the two periods. |
Drug: Selexipag
Two selexipag film-coated tablets of 200 µg as single oral dose (total dose = 400 µg)
Other Names:
Drug: Rifampicin
Rifampicin film-coated tablet of 600 mg administered orally o.d.from Day 1 to Day 9
|
| Experimental: Part 2, sequence BA Subjects participate in two study periods: During the first period (Treatment B), they receive rifampicin once daily from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 7 together with the dose of rifampicin. During the second period (Treatment A), they receive oral selexipag on Day 1. There is a washout period of 14 to 21 days between the two periods. |
Drug: Selexipag
Two selexipag film-coated tablets of 200 µg as single oral dose (total dose = 400 µg)
Other Names:
Drug: Rifampicin
Rifampicin film-coated tablet of 600 mg administered orally o.d.from Day 1 to Day 9
|
Outcome Measures
Primary Outcome Measures
- Area under the plasma concentration-time curve from zero to infinity [AUC(0-inf)] of selexipag and ACT-333679 [Blood samples at different time points from pre-dose up to 72 hours after selexipag administration in each study period (except for the period with co-administration of gemfibrozil: up to 144 hours)]
AUC(0-inf) is calculated for selexipag and its metabolite, ACT-333679, following administration of selexipag alone or concomitantly with gemfibrozil (Part I) or rifampicin (Part II)
- Maximum plasma concentration (Cmax) of selexipag and ACT-333679 [Blood samples at different time points from pre-dose up to 72 hours after selexipag administration in each study period (except for the period with co-administration of gemfibrozil: up to 144 hours)]
Cmax is directly derived from the individual plasma concentration-time curves for selexipag and its metabolite, ACT-333679, following administration of selexipag alone or concomitantly with gemfibrozil (Part I) or rifampicin (Part II)
Secondary Outcome Measures
- Area under the plasma concentration-time curve from zero to time t of the last measured concentration above the limit of quantification [(AUC(0-t)] of selexipag and ACT-333679 [Blood samples at different time points from pre-dose up to 72 hours after selexipag administration in each study period (except for the period with co-administration of gemfibrozil: up to 144 hours)]
AUC(0-t) is calculated for selexipag and ACT-333679,following administration of selexipag alone or concomitantly with gemfibrozil (Part I) or rifampicin (Part II)
- Time to reach maximum plasma concentration (tmax) of selexipag and ACT-333679 [Blood samples at different time points from pre-dose up to 72 hours after selexipag administration in each study period (except for the period with co-administration of gemfibrozil: up to 144 hours)]
tmax is directly derived from the individual plasma concentration-time curves for selexipag and its metabolite, ACT-333679, following administration of selexipag alone or concomitantly with gemfibrozil (Part I) or rifampicin (Part II)
- Terminal elimination half-life (t1/2) of selexipag and ACT-333679 [Blood samples at different time points from pre-dose up to 72 hours after selexipag administration in each study period (except for the period with co-administration of gemfibrozil: up to 144 hours)]
t1/2 is the period of time required for the concentration levels of selexipag or ACT-333679 to be reduced by one-half, following administration of selexipag alone or concomitantly with gemfibrozil (Part I) or rifampicin (Part II)
Other Outcome Measures
- Incidence of treatment-emergent adverse events and serious adverse events [Up to 35 days (from first study drug administration to end of study visit)]
A treatment-emergent AE is any AE temporally associated with the use of a study treatment, whether or not considered related to the study treatment
- Incidence of safety events of interest [Up to 35 days (from first study drug administration to end of study visit)]
Include any abnormalities in ECG, vital signs or laboratory test results
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Signed informed consent form.
-
Male subjects aged between 18 and 55 years (inclusive) at screening.
-
Body mass index of 18.0 to 28.0 kg/m2 (inclusive) at screening.
-
Healthy on the basis of physical examination, cardiovascular assessments and laboratory tests at screening.
Exclusion Criteria:
-
Any contraindication to gemfibrozil or rifampicin treatment.
-
History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might put the subject at risk of participation in the study or interfere with the absorption, distribution, metabolism or excretion of the study treatments.
-
Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Investigator Site | Kiel | Germany | 24105 |
Sponsors and Collaborators
- Actelion
Investigators
- Study Director: Shirin Bruderer, PhD, Actelion
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AC-065-113
- 2016-000811-34